Search clinical trials for: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200

Total 86 results

Taris Biomedical LLC

Completed

Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer

Urinary Bladder Cancer

United States, Netherlands
Janssen Research & Development, LLC

Completed

A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

Urinary Bladder Neoplasms

United States, Spain
Taris Biomedical LLC
Bristol-Myers Squibb

Terminated

Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer

Bladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor... and other conditions

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)

Urinary Bladder Neoplasms

United States, France, Belgium, Japan, Korea, Republic of, United Kingdom, Russian Federation, Italy, Germany, Spain, Netherlands, Portugal, Australia, Canada, Greece, Ukraine
Taris Biomedical LLC

Completed

Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer

Urinary Bladder Cancer

Netherlands
Taris Biomedical LLC

Completed

Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder

Idiopathic Overactive Bladder With Urinary Incontinence

United States
Taris Biomedical LLC

Completed

Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury

Neurogenic Detrusor Overactivity

United States
UroGen Pharma Ltd.

Active, not recruiting

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Non-muscle Invasive Bladder Cancer | Urothelial Carcinoma Bladder | NMIBC | Urothelial Carcinoma Recurrent | Carcinoma in Situ of Bladder

United States, Italy, Spain
Janssen Research & Development, LLC

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1)

Non-Muscle Invasive Bladder Cancer

Hong Kong, United States, Denmark, Israel, China, Italy, France, Korea, Republic of, Austria, Belgium, Brazil, Spain, United Kingdom, Czechia, Germany, Argentina, Ireland, Turkey, Japan, Poland
National Cancer Center, Korea
Samsung Medical Center; Asan Medical Center; Seoul National University Hospital; Korea University Anam Hospital and other collaborators

Recruiting

The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence

Urothelial Carcinoma

Korea, Republic of
National Health Research Institutes, Taiwan
National Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaborators

Completed

A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC (BTC)

Cholangiocarcinoma | Adenocarcinoma of Gallbladder

Taiwan
Janssen Research & Development, LLC

Active, not recruiting

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)

Urinary Bladder Neoplasms

United States, France, Japan, Korea, Republic of, Belgium, Czechia, Russian Federation, Argentina, Italy, Taiwan, Hungary, Germany, China, Portugal, Spain, Austria, Poland, Turkey, Australia, Canada, India, Ukraine, Brazil, Greece, Mexico
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) (SunRISe-5)

Non-Muscle Invasive Bladder Neoplasms

United States, Korea, Republic of, France, Belgium, Brazil, China, Spain, Italy, United Kingdom, Japan, Germany, Poland, Argentina, Romania
University Hospital, Basel, Switzerland

Completed

Taste Physiology in Healthy, Normal-weight Volunteers

Exploratory Behavior

Switzerland
Sanofi
Breast Cancer Research Foundation

Completed

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
Allergan
TARIS Biomedical, Inc.

Terminated

Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis

Interstitial Cystitis

United States, Canada
Centre for Addiction and Mental Health

Completed

Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence

Substance-Related Disorders | Cocaine-Related Disorders | Cocaine Addiction

Canada
MedSIR
Hoffmann-La Roche

Completed

Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (PATHFINDER)

Triple Negative Breast Cancer

Spain, Portugal
Sun Pharmaceutical Industries Limited

Withdrawn

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)

Plaque-type Psoriasis
Sun Pharmaceutical Industries Limited

Completed

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) (reSURFACE 2)

Plaque Psoriasis
Tomsk National Research Medical Center of the Russian...

Recruiting

High-dose Inhaled NO Therapy for the pREvenvention of NP After Cardiac Surgery Under CPB

Nosocomial Pneumonia

Russian Federation
Tomsk National Research Medical Center of the Russian...

Completed

High-dose Inhaled NO Therapy for the Prevention of Nosocomial Pneumonia After Cardiac Surgery With CPB

Nosocomial Pneumonia

Russian Federation
Universidad de Granada
Ministry of Science and Innovation, Spain

Enrolling by invitation

The Role of Executive Functioning in Complex Post-Traumatic Stress Disorder Among Female Survivors of Intimate Partner Violence (BELIEVE-CPTSD)

Neuropsychological Rehabilitation Program (VIRTRAEL/LUCCIDY) | Standard Training (TAU)

Spain
Tomsk National Research Medical Center of the Russian...

Recruiting

High-dose Inhalations of Nitric Oxide in the Treatment of Pneumonia

Nosocomial Pneumonia | Community-acquired Pneumonia

Russian Federation
Taiho Pharmaceutical Co., Ltd.

Recruiting

AB122 Platform Study

Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Biliary Tract Cancer | Alveolar Soft Part Sarcoma | Advanced or Metastatic Solid Tumor

Japan
NovoCure Ltd.

Completed

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

Pancreas Adenocarcinoma

United States, China, Belgium, Czechia, Korea, Republic of, Spain, Hong Kong, France, Australia, Italy, Hungary, Germany, Croatia, Canada, Mexico, Israel, Austria, Switzerland, Brazil, Poland
Phanes Therapeutics
Merck Sharp & Dohme LLC

Recruiting

Spevatamig (PT886) for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)

Pancreatic Ductal Adenocarcinoma | Gastric or Gastroesophageal Junction Adenocarcinoma

United States
Ain Shams University

Completed

Efficacy of Coadministration of Calcitonin and Hyperbaric Bupivacaine in Spinal Anesthesia in Tramadol-abuse Patients

Analgesia

Egypt
Seoul National University Hospital

Completed

Postoperative Analgesic Effect of Subcostal TAPB for Laparoscopic Gastrectomy

Postoperative Pain

Korea, Republic of
Chang Gung Memorial Hospital
TTY Biopharm

Unknown

Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Taiwan
Sorrento Therapeutics, Inc.

Withdrawn

Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases

Malignant Tumor of Pancreas Metastatic to Liver
Alice Bertaina
California Institute for Regenerative Medicine (CIRM)

Recruiting

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

CKD Stage 4 | Cystinosis | FSGS | SLE Nephritis | SIOD

United States
University of Liege

Completed

Effect of Intrathecal Morphine on Urinary Bladder Function and Recovery in Patients Having a Cesarean Delivery

Analgesia

Belgium
Actavis Inc.

Withdrawn

Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics

Asthma
Gynecologic Oncology Group
National Cancer Institute (NCI); Medical Research Council; Southwest Oncology...

Completed

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Non-Muscle Invasive Bladder Urothelial Carcinoma | Bladder Flat Urothelial Carcinoma In Situ

United States, Guam, Puerto Rico
University of Pennsylvania

Completed

Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal (PGB-LOF)

Opioid Withdrawal

United States
Medical University of Lodz

Unknown

Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma

Asthma

Poland
Pfizer

Completed

Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects

Healthy

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Prostate Carcinoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

Nausea | Vomiting | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Extrahepatic Bile Duct Cancer | Stage II Pancreatic Cancer

United States
Alfarabi Colleges

Completed

Effect of Preoperative Oral Tramadol on Inferior Alveolar Nerve Block in Patients With Symptomatic Irreversible Pulpitis

Symptomatic Irreversible Pulpitis

Saudi Arabia
The George Institute
National Health and Medical Research Council, Australia

Completed

Theophylline and Steroids in Chronic Obstructive Pulmonary Disease (COPD) Study (TASCS)

Chronic Obstructive Pulmonary Disease

Australia
Catabasis Pharmaceuticals

Completed

Study of Edasalonexent With Midazolam and Deflazacort in Healthy Subjects

Healthy

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 | Lung Non-Small Cell Squamous Carcinoma

United States
Respirent Pharmaceuticals Co Ltd.

Completed

A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma

Asthma

Greece
OHSU Knight Cancer Institute
Merck Sharp & Dohme LLC; Oregon Health and Science University

Not yet recruiting

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | High Risk Prostate Carcinoma | Localized Prostate Adenocarcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Prostate Adenocarcinoma

United States, Canada
Heart Center BH Tuzla

Unknown

Atrial Fibrillation and By-pass Surgery

Patients With Coronary Artery Disease Scheduled for by Pass Surgery

Bosnia and Herzegovina

Search clinical trials for: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations